跳至主要内容
临床试验/ACTRN12617000394347
ACTRN12617000394347已完成1 期

A single dose, randomized, blinded, bioequivalence study of a test formulation of ferrous sulfate/ascorbic acid modified release tablet in a 2 way crossover comparison against the innovator ferrous sulfate/ascorbic acid modified release tablet conducted under fasting conditions with diet control in healthy male and female volunteers

Zenith Technology Corporation Limited0 个研究点目标入组 24 人开始时间: 2017年3月17日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
Male

入选标准

  • Healthy males
  • Aged between 18 and 55
  • Non-smoker
  • BMI between 18.5 and 30 inclusive
  • Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
  • Able to provide written informed consent

排除标准

  • Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
  • Concomitant drug therapy of any kind
  • Sensitivity to ferrous sulfate/ascorbic acid or any other similar class of medicines, or the excipients of ferrous sulfate/ascorbic acid
  • History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
  • Smoker (anyone who has smoked in the last 6 months)
  • History of alcohol or drug abuse or dependency
  • Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
  • Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

研究者

相似试验

已完成
1 期
Comparative assessment of the absorption of a generic formulation of 50 mg desvenlafaxine extended release tablet against the innovator 50 mg desvenlafaxine extended release tablet conducted under fasting conditions in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of desvenlafaxine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, desvenlafaxine belongs to a class of medicines called Serotonin-Nonadrenaline Reuptake Inhibitors and is an antidepressant prescribed for the treatment and prevention of relapse of depression.Bioequivalence study conducted in healthy volunteers comparing two formulations of desvenlafaxine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, desvenlafaxine belongs to a class of medicines called Serotonin-Nonadrenaline Reuptake Inhibitors and is an antidepressant prescribed for the treatment and prevention of relapse of depression.Other - Research that is not of generic health relevance and not applicable to specific health categories listed above
ACTRN12615000832572Zenith Technology Corp Ltd22
已完成
1 期
Comparative assessment of the absorption of a generic formulation of quetiapine prolonged release tablet against the innovator quetiapine tablet conducted under fasting conditions in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Other - Research that is not of generic health relevance and not applicable to specific health categories listed above
ACTRN12613001131741Zenith Technology Corporation Limited36
已完成
1 期
Comparative assessment of the absorption of a generic formulation of 50 mg quetiapine prolonged release tablet against the innovator 50 mg quetiapine tablet conducted under fasting conditions in healthy male and female volunteers.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Other - Research that is not of generic health relevance and not applicable to specific health categories listed above
ACTRN12613001133729Zenith Technology Corporation Limited44
已完成
1 期
Comparative assessment of the absorption of a generic formulation of metformin XR tablet against the innovator metformin SR prolonged release tablet conducted under fed conditions in healthy male and female volunteers
ACTRN12615000139572Zenith Technology Corp Ltd24
已完成
1 期
Comparative assessment of the absorption of a generic formulation of fingolimod capsule against the innovator fingolimod capsule conducted under fed conditions in healthy male and female volunteers
ACTRN12614000599673Zenith Technology Corporation Limited26